Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc, a life sciences company focusing on cancer treatments and diagnostics, has announced the cash settlement of £3.13 million for the latest quarterly payment on its Convertible Bonds. This move, aimed at reducing potential shareholder dilution and considering the company’s financial health, lowers the bond principal to £33.15 million. Avacta also confirms that it is on target to meet its second half-year objectives for 2024, including updates on its AVA6000 clinical program.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
